Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ionis Pharmaceuticals, Inc.
With
AstraZeneca
Participants who were randomized in Study ION-682884-CS2 (NCT04136171) and have had a baseline scintigraphy scan will be offered the opportunity to participate in this sub-study which involves optional scintigraphy scans.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have been properly randomized into the ION-682884-CS2 study (NCT04136171) and should have had a baseline scintigraphy scan (99mTc-DPD, 99mTc- PYP, and 99mTc-HMDP) within 12 months prior to screening for ION-682884-CS2 with planar and SPECT or SPECT/CT images that can be read by the central reader.
You may not be if
Must not have weight or body girth that exceeds the limits of the equipment specifications.
Should not have any previously reported hypersensitivity reaction to Technetium-99m.